Availablity in Hospital Keningau:
- Verorab (PVRV - purified inactivated rabies vaccine, prepared on vero cell) – Sanofi Pasteur
Risk Category:
RISK CATEGORY
|
TYPE OF EXPOSURE
|
ACTION TO BE TAKEN
|
1
|
Touching/feeding animal.
Licking of intact skin.
|
Nil if history is
reliable.
If history not reliable,
treat as category 2.
|
2
|
Nibbling of uncovered
skin.
Superficial scratch, no
bleeding.
Licking of broken skin.
|
Apply wound treatment.
Administer vaccine.
Do not administer
anti-rabies immunoglobulin.
Stop vaccination if animal
is rabies negative in laboratory tests, or remains healthy after 10 -14 days
observation (dog or cat). Continue vaccination if animal is not
found/captured.
|
3
|
Bites/scratches which
penetrate the skin and draw blood.
Licking mucous membrane.
Multiple bites.
Any wild animals bites
|
Apply wound treatment.
Administer vaccine.
Administer anti-rabies
immunoglobulin.
Administer anti-tetanus
and antibiotic treatment.
Stop vaccination if animal
is rabies negative in laboratory tests, or remains healthy after 10 - 14 days
observation (dog or cat). Continue vaccination if animal is not
found/captured.
|
- Effective treatment soon (within a few days, but as soon as possible) after exposure to rabies can prevent the onset of symptoms and death.
- Post-exposure prevention consists of local treatment of the wound, administration of rabies immunoglobulin (if indicated), and immediate vaccination
Post Exposure Vaccine (PEP)
- Indicated for Risk Category 2 and 3
- Vaccination after exposure (post-exposure) is recommended for all individuals who have had contact with an animal (e.g., bites or abrasions) that they believe may be, or which is proven to be, rabid.
- Area for injection for vaccine;
- i. Adult - IM at deltoid area
- ii. Children – IM at anterolateral aspect of thigh.
- Pregnancy and Infancy are never contraindications to PEP.
Status
|
Dosing
|
Previously unvaccinated
people
|
|
Previously vaccinated people
|
|
Immunocompromised patient
(corticosteroids, other
immunosuppressive agents, chloroquine, and immunosuppressive illnesses e.g.
congenital immunodeficiency, HIV, leukaemia, lymphoma, generalized
malignancy)
|
|
Rabies Immunoglobulin:
- Rabies Immunoglobulin is indicated for Risk Category 3 only
- Human anti-rabies immunoglobulin(HRIG)-20iu/kg body weight
- Heterologous (equine) immunoglobulin(RIG) -40iu/kg body weight
- Route of administration: IM at an anatomical site distant from vaccine administration.
- If immunoglobulin is not available, it can be delayed up to 7 days post 1st vaccine given.
- Beyond the seventh day, RIG is not recommended since an antibody response to the vaccine is presumed to have occurred.
References:
- Interim Guideline for Human Rabies Prevention and Control in Malaysia.
- http://www.who.int/rabies/human/postexp/en/
- WHO Guide for Rabies Pre and Post Exposure Prophylaxis In Humans
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.